Shanghai University of Traditional Chinese Medicine’s TCM Drug OK’d to Begin US Phase II Clinical Trials for Hepatitis C At University of California, San Diego (UCSD) By FDA

ChinaBio Today -- The FDA has granted a permit to begin a Phase II trial of Fuzheng Huayu capsules in patients who have hepatitis C and have developed fibrosis of the liver. The trial will be conducted by researchers at the University of California at San Diego. Fuzheng Huayu could become the first TCM to win approval from the FDA, if all goes well. Fuzheng Huayu was developed by the Shanghai University of Traditional Chinese Medicine. It has been used in China since 2002, where it is produced by the Shanghai Sundise Chinese Medicine Technology Development Co.